Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Pfizer Inc. (PFE) Financial Analysis and Rating
Comparison Analysis Based on SEC Data
| Company Name | Pfizer Inc. |
| Industry (SIC) | 2834 - Pharmaceutical Preparations |
| Revenue in 2025 | $62,579 million (ranked #5 out of 508 companies in the industry) |
| Assets as of 12/31/2025 | $208,160 million (ranked #1) |
| Market Cap | $162,127 million (Sep 4, 2026) |
| Analyzed report | 12/31/2024 (filed 2/27/2025) |
Year:
Financial Position and Performance
| Compared with 2024 industry ratios | Change during the year |
|---|---|
|
worse |
unchanged |
| Compared with all listed companies |
|---|
|
about the same |
Financial Ratios Benchmarking
| Financial Ratio | Comparison of company ratios for 2024 | ||
|---|---|---|---|
|
with industry ratios (28 - Chemicals And Allied Products) |
with all listed companies | ||
| Solvency Ratios | |||
| Debt ratio |
0.59
0.48
|
0.59
0.61
|
|
| Debt-to-equity ratio |
1.41
0.67
|
1.41
1.35
|
|
| Liquidity Ratios | |||
| Current Ratio |
1.17
3.20
|
1.17
1.78
|
|
| Quick Ratio |
0.74
1.84
|
0.74
1.06
|
|
| Cash Ratio |
0.48
1.81
|
0.48
0.59
|
|
| Profitability Ratios | |||
| Profit margin |
12.6%
-108.7%
|
12.6%
3%
|
|
| ROE (Return on equity), after tax |
9%
-36.2%
|
9%
5.1%
|
|
| ROA (Return on assets) |
3.6%
-25.1%
|
3.6%
0.9%
|
|
| Activity Ratios | |||
| Asset turnover (days) |
1265
1274
|
1265
776
|
|
| Receivables turnover (days) |
65
60
|
65
48
|
|
| Resulting score | -0,2 | -0,1 | |
Year:
Additional Ratios (not used in score calculation)
| Financial Ratio | Comparison of company ratios for 2024 | ||
|---|---|---|---|
|
with industry ratios (28 - Chemicals And Allied Products) |
with all listed companies | ||
| Profitability Ratios | |||
| Gross margin |
71.9%
54.8%
|
71.9%
43.6%
|
|
| Activity Ratios | |||
| Inventory turnover (days) |
216
135
|
216
88
|
|
| Price Ratios | |||
| Earnings per Share (basic) | $1.42 | ||
| Earnings per Share (diluted) | $1.41 | ||
Auditor's Conclusion
We have performed a comparative analysis of the balance sheet and income statement of Pfizer Inc. (hereafter – the "Company") for the year 2024 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from 2024 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.
Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of Pfizer Inc. in 2024 is worse than the typical financial condition of companies in the "Pharmaceutical Preparations" industry.
The average ratios for this industry are higher than the average for all companies. Therefore, the Company shows a satisfactory result compared to all